ABIGAIL SOUZA, FNP-C
Family Nurse Practitioner · LAS VEGAS, NV
Individual Active NPI 1003499013
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 740 | 622,215.5 | $24,469,704 | $11,524,221 | $9,189,633 |
| 2023 | 83 | 42,429 | $3,293,625 | $1,561,447 | $1,243,314 |
| 2022 | 126 | 179 | $28,268 | $15,162 | $11,340 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 277,702 | $1 | $1 |
| J9332 | Injection, efgartigimod alfa-fcab, 2mg | 76,200 | $32 | $25 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 44,520 | $11 | $9 |
| J1306 | Injection, inclisiran, 1 mg | 34,081.5 | $12 | $9 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 29,706 | $22 | $17 |
| J3262 | Injection, tocilizumab, 1 mg | 17,800 | $6 | $5 |
| J0897 | Injection, denosumab, 1 mg | 12,901 | $26 | $21 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 8,820 | $18 | $14 |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | 7,400 | $18 | $14 |
| J2357 | Injection, omalizumab, 5 mg | 6,630 | $38 | $30 |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 5,100 | $11 | $9 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3,620 | $32 | $25 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | 830142 | NV |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in Nevada
- NPI 1548085491
- NPI 1205931656
- NPI 1578392783
- NPI 1679349062
- NPI 1851223309
- NPI 1053767335
- NPI 1609692995
- NPI 1730743451
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.